Universitätspublikationen
Refine
Year of publication
- 2015 (3) (remove)
Document Type
- Doctoral Thesis (3) (remove)
Language
- English (3) (remove)
Has Fulltext
- yes (3)
Is part of the Bibliography
- no (3)
Institute
- Medizin (3) (remove)
The small leucine-rich proteoglycan biglycan (Bgn) is a part of the extracellular matrix providing structure and enhancing fibril stability. In its soluble form, biglycan is able to bind and signal via the innate immune receptors Toll-like receptor (TLR) 2 and 4, thereby activating MAP-kinases and the NF-κB pathway. In macrophages soluble biglycan induces the secretion of several cytokines and chemokines, including TNF-α, CCL2, CXCL5 and CXCL13. A unique feature of biglycan is its ability to stimulate the secretion of mature IL-1β. By orchestrating TLR2 and 4 with the purinergic P2X4 and P2X7 receptor signalling biglycan triggers the activation of the NLRP3/ASC inflammasome, which in turn activates caspase-1 to cleave pro-IL-1β to mature IL-1β. Furthermore, in several inflammatory diseases an upregulated biglycan expression is found. Enhanced levels of biglycan could be measured in plasma and inflamed tissue. In mouse models of sepsis, lupus nephritis and renal ischemic reperfusion injury, biglycan-deficiency improved the disease outcome. Overexpression of soluble biglycan on the other hand increased immune cell infiltration into the kidney by inducing cytokine and chemokine expression in a TLR2/4-dependent manner. These studies emphasise its importance in inflammatory processes, especially in the kidney. Furthermore, the pro-inflammatory effects on macrophages and diseases established biglycan as a danger signalling molecule, yet its role as a soluble molecule in plasma was not further investigated.
Although an increase of soluble biglycan in the circulation could be seen in several inflammatory diseases, the source is not fully unravelled. Previously it could be shown that macrophages and dendritic cells secrete soluble biglycan after stimulation with IL-6 and TGF-β1. However, since these cell are resident in organs and do not circulate in the blood stream their contribution to soluble biglycan levels in plasma is likely minor. Therefore, monocytes as precursor of both macrophages and dendritic cells were investigated as a possible source of circulating biglycan. Analysis of blood from septic patients revealed elevated soluble biglycan levels as well as an increased number of monocytes. Isolated monocytes from healthy volunteers incubated with the inflammatory cytokines IL-1β, IL-6 and TGF-β1 displayed increased biglycan mRNA expression and secretion of soluble biglycan into the supernatant, revealing monocytes as a producer of soluble biglycan in blood. Therefore this work was directed to further investigate the influence of soluble biglycan on circulating monocytes, with regard to sepsis.
Monocytes can be classified into three subtypes, while the classical monocytes express CD14 (CD14++CD16low), intermediate monocytes express both CD14 and CD16 (CD14++CD16+) and non-classical monocytes express mainly CD16 (CD14lowCD16++). The intermediate and non-classical monocytes make up about 10 % of all monocytes and are referred to as CD16-positive subtypes. The CD16-positive monocytes express higher levels of TNF-α and IL-1β upon stimulation and display different migration behaviour. In most inflammatory diseases an expansion of CD16-positive monocytes is observed, especially an increased number of intermediate monocytes frequently correlate with disease severity and mortality. Since septic patients had increased circulating biglycan levels and augmented CD16-positive monocytes, a possible correlation between these two parameters was investigated. Using FACS analysis of biglycan-stimulated monocytes from healthy donors revealed a significant shift from classical to intermediate and non-classical monocytes. This shift was mediated by increased expression of CD14 and CD16 on mRNA and protein levels upon biglycan treatment. Furthermore, biglycan induced the mRNA expression of the adhesion molecules ICAM-1, VCAM-1 and ELAM-1 in CD14-positive monocytes. Four hours after biglycan stimulation an increased ICAM-1 protein expression on the cell surface of classical and intermediate monocytes was observed. Additionally, biglycan-treated CD14-positive monocytes rolled and attached to pre-stimulated endothelial cells to a greater extent compared to untreated monocytes. This demonstrates that biglycan not only triggers the expression of CD14 and CD16 but also induces a functional shift of monocytes. ...
Background: Alzheimer’s Disease (AD) is the most common form of dementia and one of the major diseases of old age, causing the impairment of cognitive functions. This disease does not only confront society with financial issues, but also puts severe stress on individuals suffering from AD and their relatives alike. One of the possible symptoms, commonly described in AD, is the impairment of learning as well as the recognition of face-name associations. Beginning at age 60, the chance to develop AD grows exponentially with increasing age, making age a major risk factor. Additionally, the e4 allele of the apolipoprotein E (APOE) polymorphism has been associated with the risk of developing AD when compared to the more common e3 allele. While strong evidence shows a stronger decline in cognitive function with rising age for e4 carriers, some studies demonstrated better cognitive function in e4 carriers at a young age.
This led to the postulation of the hypothesis of antagonistic pleiotropy of the APOE gene, wherein the e4 allele may benefit cognitive function in young carriers, yet leads to a faster decline at a later point in life, encouraging the development of cognitive dysfunction such as AD. Several functional magnetic resonance imaging (fMRI) studies, examining functional activation patterns, found APOE-related differences in key areas of episodic memory, such as the hippocampus, where e4 carriers show aberrant activation similar to AD patients. However, associative memory (encoding and retrieval of face name pairs) has not been well examined for APOE-related differences. Interaction effects of age and the APOE genotype, such as those postulated by the hypothesis of antagonistic pleiotropy, have not been addressed in face-name association tasks either.
Leading Question: Is it possible to detect interaction effects between age and APOE genotype on cognitive performance or neuronal activation patterns in healthy young and old participants during an fMRI face-name association task, supporting the hypothesis of antagonistic pleiotropy of the APOE genotype?
Methods: Participants were stratied by age, and APOE e4 carriers were randomly matched with homozygous e3 carriers. Neuropsychological examination (CVLT and CERAD) was administered. Participants underwent structural MRI analysis via voxelbased morphometry (VBM) as well as fMRI imaging during a face-name association task.
Results: Apart from strong age-related effects in cognitive function detected during neuropsychological testing, the behavioral data from the face-name association task as well as the structural MRI analysis did not show an association with the APOE genotype. Nevertheless, analysis of functional MRI data showed age- as well as APOE-dependent effects on activation patterns for the encoding and retrieval of face-name pairs, in absence of differences in cognitive performance. Further analysis showed eight clusters of significant age X APOE genotype interactions in areas previously associated with working and visual associative memory, including the fusiform gyri bilaterally. These interactions show different patterns, whereas a relative hypoactivation of young e4 carriers together with a hyperactivation of old e4 carriers is the most prominent.
Conclusions: With regard to the leading question, this study successfully found age X APOE interactions in a face-name pair retrieval task, although no interaction effects were present in the encoding task, structural analysis, or cognitive performance. The agemediated effect of the APOE e4 allele on functional activation patterns may be explained by the compensatory hypothesis, describing a relative hyperactivation of old e4 carriers as compensatory, and interpreting a relative hypoactivation of younger e4 participants as reduced effort to achieve the same cognitive performance as non carriers.
These findings present further evidence of an antagonistic pleiotropy of the APOE genotype, showing age-dependent effects of the e4 allele even in healthy carriers. Nevertheless, previously described differences in cognitive performance and brain structure, even in young participants, were not found. On the contrary, functional MRI analysis showed APOE-related differences in young and old participants, suggesting that this modality may be more sensitive in detecting APOE-mediated changes. Among the clusters, demonstrating an interaction effect, the fusiform gyri were most prominent, which might be due to its important role in visual associative memory. As previous studies indicate an early and strong involvement of this area due to AD pathology, this interaction effect of age and APOE genotype in healthy participants underlines the importance of this region in the development of AD, and should be the focus of further research. However, this research is also required to determine, how exactly the APOE genotype influences brain function in healthy humans, and to clarify its relationship to pathological processes facilitating the development of AD.
Hypertension is a primary risk factor for cardiovascular diseases including myocardial infarction and stroke. Major determinants of blood pressure are vasodilatory factors such as nitric oxide (NO) released from the endothelium under the influence of fluid shear stress exerted by the flowing blood. Defects in flow-induced NO formation go along with endothelial dysfunction, initiation and progression of atherosclerosis as well as with arterial hypertension. Previous work has identified several mechanotransducing signaling processes involved in fluid shear stress-induced endothelial effects. But how fluid shear stress initiates the response is poorly understood. Here, I show in human and bovine endothelial cells that the G-protein Gq/G11 and the purinergic receptor P2Y2 mediate fluid shear stress-induced endothelial responses such as Ca2+ release, nitric oxide (NO) formation and the phosphorylation of platelet-endothelial-cell-adhesion-molecule-1 (PECAM-1), vascular endothelial growth factor-2 (VEGFR-2) and Akt kinase as well as activation of the endothelial NO synthase (eNOS). P2Y2 receptor is activated by adenosine triphosphate (ATP) which is released from endothelial cells under the influence of fluid shear stress. Arteries with P2Y2 or Gαq/Gα11 deficiency have impaired flow-induced dilatation. Mice with induced endothelium-specific deficiency of P2Y2 or Gαq/Gα11 develop hypertension which is accompanied by reduced eNOS activation. My data identify P2Y2 and Gq/G11 as a critical endothelial mechano-signaling pathway located upstream of mechanotransducing processes described so far. Moreover, I demonstrate that P2Y2 and Gq/G11 are required for basal endothelial NO formation, vascular tone and blood pressure.